<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

Other researchers are eager to play that role. At USC, a team led by Dr. Heinz-Josef Lenz will be testing baricitinib and remdesivir in a clinical trial with 59 COVID0-19 patients, while another group at the University of Colorado’s Anschutz Medical Campus turned on a dime to design a clinical trial of baricitinib in 80 COVID-19 patients. “As a general principle, reproducibility in science is a central pillar,” said Dr. Joaquin Espinosa, who is leading the work in Colorado.